NPSP CHMP Europe's FDA says yes:
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome
European CHMP adopts positive opinion for teduglutide (Revestive®) for patients with short bowel syndrome (SBS)
SBS is a rare and highly disabling condition that impacts patients’ quality of life and can lead to serious life-threatening complications
Teduglutide has received orphan drug designation for the treatment of SBS from the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA)
Business Wire
